Building on its expertise, BIO Ventures for Global Health (BVGH) commits to strengthening and expanding efforts to target diseases of the poor by bringing together interested parties and disseminating vital information from its research. To do this, BVGH will unveil the Innovation Map in late 2007, which will outline the specific areas where biotechnologies can be applied to target malaria, tuberculosis and the three trypanosomal diseases. The Innovation Map will enable those companies with the appropriate abilities and platform technologies to develop viable partnership opportunities to advance product development.
From Acambis' ChimeraVaxTM-JE for Japanese encephalitis to AVANT's Rotarix for rotavirus, there is a respectable list of products of biopharmaceutical origin specifically targeting the neglected diseases that disproportionately affect the world's poorest citizens. The number of lives saved and Disability Adjusted Life Years (DALY) averted due to these products is increasing every day, and there is no longer any doubt about the promise held within the industry for the diagnosis, treatment and prevention of these global killers.
BVGH is founded on the realization and advancement of this great potential. The company believes that building partnerships with the biopharmaceutical industry and fostering new collaborations among its members is one of the most effective ways to enhance treatments and strategies for eliminating Neglected Tropical Diseases.